tDCS on Parkinson's Disease Cognition
Parkinson's disease (PD) has been classically regarded as a "movement disorder", so earlier work has focused on treating motor symptoms only. As PD patients now have longer life expectancy, the relatively slowly progressing cognitive deficits (compared to their motor deficits) have become one of the major challenges. A
| Condition(s) | Parkinson Disease, Mild Cognitive Impairment |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Parkinson's disease (PD) has been classically regarded as a "movement disorder", so earlier work has focused on treating motor symptoms only. As PD patients now have longer life expectancy, the relatively slowly progressing cognitive deficits (compared to their motor deficits) have become one of the major challenges. Approximately 80% of PD patients eventually become demented. Therefore cognitive dysfunction is one of the most significant factors affecting the quality of life of patients with PD. While dementia in Parkinson's disease is routinely treated by cholinesterase inhibitors (e.g., donepezil and rivastigmine), their efficacy on mild cognitive impairment found in non-demented PD is questionable. Alternative approaches have been proposed including transcranial direct current stimulat |
| Who can participate | Inclusion Criteria: * Patients must meet diagnostic criteria for idiopathic Parkinson's disease, defined as the presence of two or more of the cardinal clinical features of PD in the absence of known causes of parkinsonism such as encephalitis or neuroleptic treatment * Ability to provide written informed consent * defined by the Diagnostic and Statistical Manual of Mental Disorders; DSM-5) * Age \> 40 * fluent in English. * Patients' cognitive statuses will be evaluated by the participating neuropsychiatrist or a trained psychiatry or neurology resident. Exclusion Criteria: * Patients with dementia (defined as a Montreal Cognitive Assessment score \< 18) * Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities, ataxia, sensory loss, or pyramidal signs. * Abn |
| Ages | 40 Years |
| Sex | All |
| Lead sponsor | University of Manitoba |
| Locations | Winnipeg, Manitoba, Canada |
| Start date | 2017-03-22 |
| NCT ID | NCT03025334 |
| Official listing | https://clinicaltrials.gov/study/NCT03025334 |